- Research article
- Open Access
Assessment of three Resistance-Nodulation-Cell Division drug efflux transporters of Burkholderia cenocepaciain intrinsic antibiotic resistance
© Buroni et al; licensee BioMed Central Ltd. 2009
- Received: 25 March 2009
- Accepted: 17 September 2009
- Published: 17 September 2009
Burkholderia cenocepacia are opportunistic Gram-negative bacteria that can cause chronic pulmonary infections in patients with cystic fibrosis. These bacteria demonstrate a high-level of intrinsic antibiotic resistance to most clinically useful antibiotics complicating treatment. We previously identified 14 genes encoding putative Resistance-Nodulation-Cell Division (RND) efflux pumps in the genome of B. cenocepacia J2315, but the contribution of these pumps to the intrinsic drug resistance of this bacterium remains unclear.
To investigate the contribution of efflux pumps to intrinsic drug resistance of B. cenocepacia J2315, we deleted 3 operons encoding the putative RND transporters RND-1, RND-3, and RND-4 containing the genes BCAS0591-BCAS0593, BCAL1674-BCAL1676, and BCAL2822-BCAL2820. Each deletion included the genes encoding the RND transporter itself and those encoding predicted periplasmic proteins and outer membrane pores. In addition, the deletion of rnd-3 also included BCAL1672, encoding a putative TetR regulator. The B. cenocepacia rnd-3 and rnd-4 mutants demonstrated increased sensitivity to inhibitory compounds, suggesting an involvement of these proteins in drug resistance. Moreover, the rnd-3 and rnd-4 mutants demonstrated reduced accumulation of N-acyl homoserine lactones in the growth medium. In contrast, deletion of the rnd-1 operon had no detectable phenotypes under the conditions assayed.
Two of the three inactivated RND efflux pumps in B. cenocepacia J2315 contribute to the high level of intrinsic resistance of this strain to some antibiotics and other inhibitory compounds. Furthermore, these efflux systems also mediate accumulation in the growth medium of quorum sensing molecules that have been shown to contribute to infection. A systematic study of RND efflux systems in B. cenocepacia is required to provide a full picture of intrinsic antibiotic resistance in this opportunistic bacterium.
- Efflux Pump
- Efflux System
- Homoserine Lactone
Burkholderia cenocepacia is a member of the Burkholderia cepacia complex (Bcc), a group of phenotypically similar Gram-negative bacteria  that are opportunistic pathogens and sometimes cause serious life-threatening infections in cystic fibrosis (CF) patients [2, 3]. Infection in CF patients may result in asymptomatic carriage, but often leads to a rapid decline of the lung function and in some cases to the "cepacia syndrome", characterized by necrotizing pneumonia and sepsis .
B. cenocepacia and other members of the Bcc demonstrate high-levels of intrinsic resistance to most clinically relevant antibiotics, complicating the treatment of the infection . Multi-drug resistance in CF isolates is defined as resistance to all of the agents in two of three classes of antibiotics, such as quinolones, aminoglycosides, and β-lactam agents, including monobactams and carbapenems . Multiple antibiotic resistances in Bcc bacteria have been attributed to reduced permeability of the bacterial outer membrane [7–9], expression of antibiotic modifying enzymes , and alteration of cellular targets . Information relating to the contribution that drug efflux systems play in the drug resistance of Bcc bacteria is limited, as only a few multi-drug efflux pumps have been described to date in some clinical isolates [12–14]. In contrast, the contribution of multidrug efflux systems to antibiotic resistance in clinical isolates of Pseudomonas aeruginosa, another CF pathogen, is well documented. Two P. aeruginosa efflux pumps, MexAB-OprM and MexXY-OprM, contribute to intrinsic multidrug resistance, while MexCD-OprJ and MexEF-OprN are responsible for the acquired antimicrobial resistance of different mutant strains .
RND transporters are important mediators of multi-drug resistance in Gram-negative bacteria . RND transporters form protein complexes that span both the cytoplasmic and outer membrane. The complex comprises a cytoplasmic membrane transporter protein, a periplasmic-exposed membrane adaptor protein, and an outer-membrane channel protein. The Escherichia coli AcrAB-TolC and the P. aeruginosa MexAB-OprM complexes are extremely well characterized and the three-dimensional structures of various components have been resolved [17–21].
Two RND type multi-drug efflux pumps, AmrAB-OprA and BpeAB-OprB, have been described in Burkholderia pseudomallei (the causative agent of melioidosis) and both confer resistance to aminoglycosides and macrolides [22, 23]. The contribution of BpeAB-OprB and AmrAB-OprA, to the intrinsic resistance of B. pseudomallei to gentamicin, streptomycin and erythromycin explains why aminoglycoside-β-lactam combinations, which are commonly used to treat suspected cases of community-acquired sepsis in any part of the world, are ineffective for the treatment of melioidosis . Furthermore, the transport of acyl homoserine lactones, involved in quorum-sensing systems of B. pseudomallei, also requires the BpeAB-OprB efflux pump . Thus, targeted inhibition of BpeAB-OprB could be therapeutically beneficial.
Several possible strategies can be considered to specifically block the activity of these drug efflux pumps, such as jamming the outer membrane channel, generating competition at the inner membrane pump, altering the pump assembling or collapsing the energy component of the mechanism . The activity of efflux inhibitors, such as diamine compounds, has been demonstrated in animal models of P. aeruginosa infections and two of them are in preclinical development .
In B. cenocepacia the significance of RND efflux systems has not been determined. However, a salicylate-regulated efflux pump that is conserved among members of the Bcc has been identified [27, 28]. We are focusing our research in the B. cenocepacia J2315 strain. This strain is a prototypic isolate belonging to an epidemic clone that has spread by cross infection to CF patients in Europe and North America . Previously, we identified 14 genes encoding putative RND efflux pumps in the genome of B. cenocepacia J2315 . After the completion of the whole genome sequence , two additional genes encoding RND pumps were discovered. Reverse transcriptase analyses showed that some of these genes are indeed transcribed at detectable levels. As a first step towards understanding the contribution of RND pumps to B. cenocepacia antibiotic resistance we deleted genes encoding putative efflux pumps, RND-1, RND-3, and RND-4, containing the genes BCAS0591-BCAS0593 (located on chromosome 3), BCAL1674-BCAL1676, and BCAL2822-BCAL2820 (located on chromosome 1), respectively. In a previous publication, the genes encoding the membrane transporter component of the efflux pump, BCAS0592, BCAL1675, and BCAL2821 were referred to as Orf1, Orf3, and Orf4, respectively . In this investigation we show that deletion of rnd-3 and rnd-4 genes is associated with increased sensitivity to certain antibiotics and reduced secretion of quorum sensing molecules.
B. cenocepaciaBCAS0592, BCAL1675, and BCAL2821 encode RND-type transporters
The operon encoding RND-3 is located on chromosome 1 and spans nucleotides 1830038 to 1834638. The first gene, BCAL1674, encodes the membrane fusion protein, a predicted 406-aa protein. The product of the downstream gene is a predicted 1046-aa protein that functions as an RND transporter. The third gene, BCAL1676, encodes the 486-aa outer membrane pore protein [Fig. 1]. BLASTP results revealed that BCAL1674 had 79 and 48% identity with the membrane fusion proteins AmrA (B. pseudomallei) and MexC (P. aeruginosa), while BCAL1675 was similar to AmrB (B. pseudomallei, 86%) and to MexD of P. aeruginosa (52%), both encoding the RND transporter. BCAL1676 was highly related to the outer membrane proteins OprA of B. pseudomallei (78% of identity) and OprM of P. aeruginosa (47%) and again possessed the predicted conserved structural features of outer membrane proteins that function in RND efflux systems. A gene encoding a predicted TetR family regulator protein (BCAL1672) is located upstream of BCAL1674 but is transcribed in the opposite direction [Fig. 1].
Lastly, the predicted operon encoding RND-4, comprising the genes BCAL2820, BCAL2821 and BCAL2822, is located on chromosome 1 and spans nucleotides 3095788 to 3101801 [Fig. 1]. BCAL2821 encodes the 1066-aa RND transporter protein, which is highly related to BpeB from B. pseudomallei (94% identity) and to MexB (P. aeruginosa, 64% identity). BCAL2820 encodes the 507-aa outer membrane protein related to OprB (B. pseudomallei, 84% identity) and to OprM from P. aeruginosa (53% identity). BCAL2822 encodes a predicted 424-aa membrane fusion protein highly similar to BpeA from B. pseudomallei (89% identity) and to MexA from P. aeruginosa (54% identity).
To demonstrate a role for these efflux pumps in the intrinsic antibiotic resistance of B. cenocepacia J2315, we attempted the construction of single deletion mutants of each rnd gene using the method described by Flannagan et al.  (see Methods). The deletion mutagenesis strategy requires expression of the endonuclease I-SceI and allows for the creation of unmarked gene deletions. While attempting to generate the deletion mutants we encountered difficulties selecting recombinant colonies at a high concentration of antibiotics. Similarly we also failed to identify positive colonies having targeted integration of the deletion plasmid. The latter was particularly difficult for our initial attempts to get single deletions of each of the rnd genes. We reasoned that the flanking regions of the rnd genes, which are cloned into the mutagenesis plasmid pGPI-SceI to mediate targeted integration into the chromosome, share significant sequence identity between different rnd genes throughout the B. cenocepacia genome. Due to these difficulties we concluded that single gene deletions could not be possible using the I-SceI mutagenesis strategy. To circumvent this problem we generated plasmids designed to delete the entire operons encoding the three different efflux systems, as the DNA flanking the operons was not similar between different operons encoding efflux systems. This strategy resulted in the mutant strains D1 (ΔBCAS0591-BCAS0593), D3 (ΔBCAL1672-BCAL1676), and D4 (ΔBCAL2820-BCAL2822). In the case of strain D3, the deletion not only included the rnd operon but also BCAL1672, encoding a putative TetR regulator. The presence of the correct deletion in each strain was confirmed by PCR analysis and Southern blot hybridization (data not shown).
Effect of deletion of efflux pumps operons on B. cenocepaciaJ2315 drug resistance
Antimicrobial susceptibilities of B. cenocepacia J2315, D3, and D4 strains
As already mentioned, the proteins BCAL1674, BCAL1675, and BCAL1676 that comprise the rnd-3 operon share strong sequence similarity to RND efflux pump AmrAB-OprA from B. pseudomallei which is responsible for the efflux of aminoglycosides and macrolides in that Burkholderia species . We previously showed that the gene encoding the pump protein (orf3) was expressed at detectable levels by RT-PCR. Assuming that RND-3 is functionally similar to AmrAB-OprA, the lack of aminoglycoside and macrolide resistance in the B. cenocepacia D3 mutant may be due to an alternative efflux pump or resistance mechanism against aminoglycosides and macrolides. To address the notion of RND efflux pump redundancy, we are in the process of generating a complete library of RND deletion mutants that can be screened for drug sensitivity. Furthermore the I-SceI deletion strategy makes it possible the construction of strains carrying multiple RND gene deletions, which we are also pursuing.
The B. cenocepacia D4 deletion mutant demonstrated a 4 to 16-fold increase in drug susceptibility to several of the antimicrobials tested, indicating that RND-4 plays an important role in the intrinsic antibiotic resistance of B. cenocepacia [Table 1]. In particular, strain D4 is more susceptible than the parental strain J2315 when exposed to aztreonam, chloramphenicol, gentamicin, tobramicin, and to different fluoroquinolones, such as nalidixic acid, ciprofloxacin, levofloxacin, norfloxacin, and sparfloxacin. Furthermore, the MIC of ethidium bromide was more than 16-fold lower in D4 than in J2315 [Table 1]. The MIC values for other drugs such as ampicillin, ceftazidime, meropenem, piperacillin, erythromycin, and kanamycin were not altered in D4 as compared to J2315 (data not shown). Increased sensitivity to many antimicrobials of therapeutic importance might suggest that inhibition of RND-4 function could be of benefit to CF patients colonized with B. cenocepacia.
Effect of broad-spectrum efflux pump inhibitor MC-207,110 on B. cenocepaciaJ2315 and the RND deletion mutants D1, D3 and D4
It has been reported that MC-207,110 efflux inhibitor has a potentiating effect in P. aeruginosa, where it lowers the MIC of different fluoroquinolones [34, 35]. We tested the effect of this efflux inhibitor on B. cenocepacia J2315 and the deletion mutants D1, D3, and D4. To initiate this analysis we determined the MIC of MC-207,110 for our bacterial strains to determine whether this compound was itself bactericidal. Exposure of J2315, D1 and D3 to MC-207,110 yielded an MIC value of 640 μg/ml. In contrast, strain D4 demonstrated a MIC to MC-207,110 of 320 μg/ml, indicating that this compound exerts some antibacterial effects and that RND-4 is required at least in part for resistance to this compound. Next, the MICs of the compounds previously used to determine resistance profiles described above were re-assessed in the presence of 40 μg/ml of MC-207,110 by the agar plate method. This concentration was selected as it is well below the MIC value determined for each strain. Exposure of the parental strain J2315 or the mutant strains generated in this study to MC-207,100 did not alter the MIC profile for any of the strains tested. This is consistent with previous observations in B. pseudomallei where this compound did not increase drug sensitivity .
Efflux of levofloxacin in B. cenocepaciaJ2315 and the D4 mutant
Moreover, to determine whether the accumulation of levofloxacin was energy-dependent, reserpine was added to cells 2.5 min after the addition of levofloxacin. As shown in Fig. 2, in the presence of reserpine, in the wild-type strain and D1 mutant, the accumulation of levofloxacin increased to levels close to the values shown by D4 mutant. This demonstrates that the accumulated levels of levofloxacin were the same under de-energized conditions. This finding suggests that reserpine is able to inhibit RND-4 efflux pump, as well as the other efflux systems in J2315 and D1 strains. The addition of reserpine also increased intracellular levofloxacin accumulation in D4 mutant [Fig. 2], suggesting that additional efflux systems are expressed in the absence of this transporter, as previously reported .
Evaluation of acyl homoserine lactone accumulation in the growth medium of B. cenocepaciaJ2315 and the D1, D3 and D4 mutants
Employing a recently developed mutagenesis strategy , we successfully deleted three operons encoding RND efflux pumps in B. cenocepacia strain J2315. This strain is notoriously difficult to manipulate genetically, in part due to its high level of antibiotic resistance, which precludes the use of the most common selectable markers for gene exchange. The mutagenesis strategy we employed has the advantage of generating markerless deletions making it possible to repeatedly use the same antibiotic resistance cassette for subsequent gene deletions. We began our study by deleting operons encoding RND-like efflux pumps in B. cenocepacia J2315. The operons were selected on the basis that they are the most closely related B. cenocepacia efflux pumps to the Mex efflux pumps in P. aeruginosa .
Our results demonstrate that only two of the three operons targeted for deletion contribute to the antibiotic resistance of B. cenocepacia under the conditions tested here, and that their function contributes to the resistance of a small subset of antibiotics. Levofloxacin was one of the antibiotics to which increased sensitivity could be detected and our data indicate that RND-4 plays a role in resistance to this drug. The inability to demonstrate increased sensitivity to most classes of antibiotics supports the notion that there is functional redundancy in the efflux pumps expressed by B. cenocepacia. Consequently, multiple RND gene deletions in the same strain may be required to understand better their role in intrinsic antibiotic resistance. The I-SceI mutagenesis system makes this possible and these experiments are currently under way in our laboratories.
Multidrug-resistance efflux pumps do not only confer antibiotic resistance, but can also function to promote colonization and persistence in the host . For example, Vibrio cholerae RND efflux systems are required for antimicrobial resistance, optimal expression of virulence genes, and colonization of the small intestine in an infant mouse model of infection . In this study, we found reduced accumulation of AHLs quorum sensing signal molecules in the growth medium of two of the RND deletion mutants. These observations suggest that these mutants have an AHL export defect that may alter quorum sensing. Importantly, it has been demonstrated that B. cenocepacia mutants lacking functional quorum sensing systems are attenuated in a rat model of lung infection . It is likely that RND-3 and/or RND-4 might also be required for survival in vivo and inhibition of their function may be beneficial not only to prevent quorum sensing dependant phenomena such as biofilm formation but also to increase antibiotic sensitivity during infection.
In summary, we have demonstrated that in B. cenocepacia, RND efflux systems contribute to antibiotic resistance and possibly to the secretion of quorum sensing molecules. Furthermore our observations indicate that further investigation of RND efflux systems in B. cenocepacia is necessary to better understand how this bacterium is able to resist antibiotic treatments in the clinic and to chronically infect cystic fibrosis patients.
Bacterial strains and growth conditions
Strains and plasmids
Strain or plasmid
Source and/or reference
CF clinical isolate
E. coli strains
F- Φ80dlacZΔM15 Δ(lacZYA-argF)U169 endA1 recA1 hsdR17(rK- mK+) supE44 thi-1 ΔgyrA96 relA1
araD Δ(lac pro) argE(Am) recA56 nalA λ pir; Rifr
Vector for PCR cloning, Ampr
oriR6K, ΩTpr, mob+, containing the ISce-I restriction site
oricolE1, RK2 derivative, Kanr, mob+, tra+
pDA12 encoding the ISce-I homing endonuclease
Plasmid for construction of D1 deletion mutant
Plasmid for construction of D3 deletion mutant
Plasmid for construction of D4 deletion mutant
Ampr, pQF50 containing PcepI-lacZ and cepR
Manipulation of DNA was performed as described previously . Restriction enzymes and T4 DNA ligase were purchased from GE Healthcare and used following the manufacturer's instructions. E. coli DH5α and E. coli SY327 cells were transformed by the electroporation method . Plasmids were mobilized into B. cenocepacia J2315 by triparental mating as described previously , using E. coli DH5α carrying the helper plasmid pRK2013. Gentamicin was used to counter select against the E. coli donor and helper strains. All PCR reactions used the MJ Mini Personal Thermal Cycler (BioRad). To amplify PCR products Taq DNA polymerase, HotStar HiFidelity Polymerase kit, Hot StarTaq DNA Polymerase or Qiagen LongRange PCR kit (QIAGEN) were used and each reaction supplemented with Q solution according to the manufacturer's instructions. DNA fragments were cloned into pGEM-T Easy vector (Promega) and sequenced using the standard M13for and M13rev primers. Southern blot analyses were performed as previously described .
Determination of MIC (Minimal Inhibitory Concentration) for B. cenocepacia J2315 and the deletion mutants D1, D3, and D4 was performed by streaking 1 × 104 cells onto LB agar containing 2-fold dilutions of different drugs. The following compounds were tested to determine the resistance profile: aztreonam, ethidium bromide, chloramphenicol, gentamicin, tobramicin, nalidixic acid, ciprofloxacin, levofloxacin, norfloxacin, sparfloxacin, ampicillin, ceftazidime, erythromycin, meropenem, piperacillin, kanamycin, tetracycline, and trimethoprim. Plates were incubated at 37°C for 3 days and the growth was visually evaluated. The MIC was defined as the lowest drug concentration that prevented visible growth. The results represent the average of three independent replicas.
The mutagenesis procedure allows for the creation of unmarked nonpolar gene deletions, as described by Flannagan et al. . Briefly, the upstream and downstream DNA sequence that flanks (about 500 bp each) the operon targeted for deletion were cloned into pGPISce-I. This suicide plasmid contains a unique restriction site for the endonuclease I-SceI. Mutagenesis plasmids were mobilized by conjugation into B. cenocepacia J2315 where they integrate into the chromosome by homologous recombination. Exconjugants were selected in the presence of trimethoprim (800 μg/ml) and the single crossover insertion of the mutagenic plasmid in the B. cenocepacia genome was confirmed by PCR analysis. Subsequently, a second plasmid, pDAISce-I (encoding the I-SceI endonuclease) was introduced by conjugation. Site-specific double-strand breaks take place in the chromosome at the I-SceI recognition site, resulting in tetracycline-resistant (due to the presence of pDAI-SceI) and trimethoprim-susceptible (indicating the loss of the integrated mutagenic plasmid) exconjugants.
Primers used in this work
The mutagenesis plasmids were mobilized into B. cenocepacia by conjugation and mutants were selected as described above. Due to the high level of antibiotic resistance displayed by B. cenocepacia J2315 we used 800 μg/ml trimethoprim and 300 μg/ml tetracycline. As the trimethoprim MIC in B. cenocepacia J2315 is very high (256 μg/ml), we used a high concentration of antibiotic (800 μg/ml). The single crossover insertion of the mutagenic plasmid in the B. cenocepacia genome was confirmed by PCR. Subsequently pDAI-SceI was introduced in the strain with the single crossover by conjugation. Site-specific double-strand breaks took place in the chromosome, resulting in exconjugants resistant to tetracycline and susceptible to trimethoprim. Also in this case we had to use a greater amount of tetracycline (300 μg/ml) respect to B. cenocepacia K56-2 (100 μg/ml), due to the high level of resistance of J2315 strain. The desired gene deletions were first confirmed by PCR amplification using primers KO1F-KO1R, CO13OPL-CO13OPR, and KO4F-KO4R for rnd-1, -3, and -4, respectively, and then by Southern blot hybridization of XhoI- (for D1 and D4 strains) or NotI- (for D3) cleaved genomic DNA.
Levofloxacin accumulation assay
The accumulation of levofloxacin in B. cenocepacia J2315 was monitored by a fluorometric method, using the PerkinElmer LS3 fluorometer. All experiments were repeated three times. B. cenocepacia J2315, D1 and D4 mutant were cultured until the cells were in an exponential growth phase (OD550 = 0.6). The cells were then harvested by centrifugation at 4°C, washed once in 50 mM sodium phosphate buffer, pH 7.0, and resuspended in the same buffer to a final OD550 equal to 20. The bacterial suspension was preincubated for 10 min at 37°C in a shaking bath. Levofloxacin was added to a final concentration of 40 μg/ml. One-milliliter aliquots were collected at different time points, chilled on ice, then centrifuged at 12000 × g for 3 min at 4°C. The pellets were washed once with 1 ml of chilled 50 mM sodium phosphate buffer, pH 7.0 and resuspended in 1 ml of 0.1 M glycine-HCl, pH 3.0. This suspension was then lysed by incubation at room temperature for 16 h, with vigorous shaking. After 16 h, the samples were then centrifuged at 12000 × g for 5 min at room temperature and the fluorescence of the supernatant was measured using the excitation and emission wavelengths of 295 and 490 nm, respectively. Levofloxacin concentrations were calculated using a standard curve of the antibiotic (concentration ranging from 0.42 μg/ml to 6.38 μg/ml) in 0.1 M glycine-HCl buffer, pH 3.0. To correct for any endogenous signal the fluorescence of a control cell lysate, measured on samples not exposed to the drug, was subtracted from the experimental values. The intracellular levels of levofloxacin were expressed as drug accumulation in 109 cells, after counting of viable cells for each time point. The accumulation of levofloxacin was determined at the following time intervals: 0 min, 0 min+ drug, 2.5 min, 5 min, 10 min, 15 min, and 20 min. To determine whether levofloxacin was actively effluxed from B. cenocepacia J2315 and the mutant strains, reserpine (8 μg/ml) was added 2.5 min after the addition of levofloxacin and the samples were treated as described above.
Purification, detection and quantification of N-acyl homoserine lactone (AHLs)
The purification, detection and visualization of AHL signal molecules from culture supernatants were performed as described previously . Bacterial strains were inoculated in 50 ml of half diluted LB and grown at 37°C with constant agitation until OD600 reached 2.5. Organic extractions with ethyl acetate (0.1% acetic acid) were performed twice on each supernatant and extracts were dried and resuspended in acidified ethyl acetate in 1/1000 of the original volume. Quantification of AHLs was determined using the reporter plasmid pSCR1. This plasmid contains the cepR gene and the cepI gene promoter controlling the expression of a promoterless β-galactosidase (lacZ) gene and functions as a sensor of AHL molecules . Overnight cultures of E. coli DH5α carrying pSCR1 were normalized to an OD600 of 0.1 in a volume of 20 ml LB containing 10 μL of the AHL purified extract (prepared as described above). 10 μL of ethyl acetate were used as negative control, while 100 nM of synthetic C8-HSL (Sigma-Fluka) was used as positive control. Cultures were then grown with agitation at 37°C for 6 h and β-galactosidase activities were determined .
The authors are grateful to Dr. Claudio Seppi (Dipartimento di Biochimica A. Castellani, University of Pavia, Italy) for fluorometer availability to perform efflux experiments. R.S.F. was supported by a studentship from the Canadian Cystic Fibrosis Foundation. M.A.V. holds a Canada Research Chair in Infectious Diseases and Microbial Pathogenesis. This research was supported by a grant from Italian Cystic Fibrosis Research Foundation (FFC). The project was adopted by FFC Delegation of Lago di Garda e Bergamo.
- Coenye T, Vandamme P, Govan JR, LiPuma JJ: Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol. 2001, 39 (10): 3427-3436. 10.1128/JCM.39.10.3427-3436.2001.PubMed CentralPubMedView ArticleGoogle Scholar
- Mahenthiralingam E, Vandamme P: Taxonomy and pathogenesis of the Burkholderia cepacia complex. Chron Respir Dis. 2005, 2 (4): 209-217. 10.1191/1479972305cd053ra.PubMedView ArticleGoogle Scholar
- Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, Levison H: Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr. 1984, 104 (2): 206-210. 10.1016/S0022-3476(84)80993-2.PubMedView ArticleGoogle Scholar
- Govan JR, Brown AR, Jones AM: Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol. 2007, 2: 153-164. 10.2217/174609220.127.116.11.PubMedView ArticleGoogle Scholar
- Waters V, Ratjen F: Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues. Expert Rev Anti Infect Ther. 2006, 4 (5): 807-819. 10.1586/1478718.104.22.1687.PubMedView ArticleGoogle Scholar
- Saiman L, Siegel J, Cystic Fibrosis Foundation: Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol. 2003, 24 (Suppl 5): S6-52. 10.1086/503485.PubMedView ArticleGoogle Scholar
- Aronoff SC: Outer membrane permeability in Pseudomonas cepacia : diminished porin content in a beta-lactam-resistant mutant and in resistant cystic fibrosis isolates. Antimicrob Agents Chemother. 1988, 32 (11): 1636-1639.PubMed CentralPubMedView ArticleGoogle Scholar
- Moore RA, Hancock RE: Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Chemother. 1986, 30 (6): 923-926.PubMed CentralPubMedView ArticleGoogle Scholar
- Parr TR, Moore RA, Moore LV, Hancock RE: Role of porins in intrinsic antibiotic resistance of Pseudomonas cepacia . Antimicrob Agents Chemother. 1987, 31 (1): 121-123.PubMed CentralPubMedView ArticleGoogle Scholar
- Trépanier S, Prince A, Huletsky A: Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997, 41 (11): 2399-2405.PubMed CentralPubMedGoogle Scholar
- Burns JL, Lien DM, Hedin LA: Isolation and characterization of dihydrofolate reductase from trimethoprim-susceptible and trimethoprim-resistant Pseudomonas cepacia. Antimicrob Agents Chemother. 1989, 33 (8): 1247-1251.PubMed CentralPubMedView ArticleGoogle Scholar
- Burns JL, Wadsworth CD, Barry JJ, Goodall CP: Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob Agents Chemother. 1996, 40 (2): 307-313.PubMed CentralPubMedGoogle Scholar
- Fehlner-Gardiner CC, Valvano MA: Cloning and characterization of the Burkholderia vietnamiensis norM gene encoding a multi-drug efflux protein. FEMS Microbiol Lett. 2002, 215 (2): 279-283. 10.1111/j.1574-6968.2002.tb11403.x.PubMedView ArticleGoogle Scholar
- Wigfield SM, Rigg GP, Kavari M, Webb AK, Matthews RC, Burnie JP: Identification of an immunodominant drug efflux pump in Burkholderia cepacia. J Antimicrob Chemother. 2002, 49 (4): 619-624. 10.1093/jac/49.4.619.PubMedView ArticleGoogle Scholar
- Poole K, Srikumar R: Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr Top Med Chem. 2001, 1 (1): 59-71. 10.2174/1568026013395605.PubMedView ArticleGoogle Scholar
- Poole K: Efflux-mediated multiresistance in Gram-negative bacteria. Clin Microbiol Infect. 2004, 10 (1): 12-26. 10.1111/j.1469-0691.2004.00763.x.PubMedView ArticleGoogle Scholar
- Akama H, Matsuura T, Kashiwagi S, Yoneyama H, Narita S, Tsukihara T, Nakagawa A, Nakae T: Crystal structure of the membrane fusion protein, MexA, of the multidrug transporter in Pseudomonas aeruginosa. J Biol Chem. 2004, 279 (25): 25939-25942. 10.1074/jbc.C400164200.PubMedView ArticleGoogle Scholar
- Akama H, Kanemaki M, Yoshimura M, Tsukihara T, Kashiwagi T, Yoneyama H, Narita S, Nakagawa A, Nakae T: Crystal structure of the drug discharge outer membrane protein, OprM, of Pseudomonas aeruginosa: dual modes of membrane anchoring and occluded cavity end. J Biol Chem. 2004, 279 (51): 52816-52819. 10.1074/jbc.C400445200.PubMedView ArticleGoogle Scholar
- Higgins MK, Bokma E, Koronakis E, Hughes C, Koronakis V: Structure of the periplasmic component of a bacterial drug efflux pump. Proc Natl Acad Sci USA. 2004, 101 (27): 9994-9999. 10.1073/pnas.0400375101.PubMed CentralPubMedView ArticleGoogle Scholar
- Koronakis V, Sharff A, Koronakis E, Luisi B, Hughes C: Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. Nature. 2000, 405 (6789): 914-919. 10.1038/35016007.PubMedView ArticleGoogle Scholar
- Murakami S, Nakashima R, Yamashita E, Yamaguchi A: Crystal structure of bacterial multidrug efflux transporter AcrB. Nature. 2002, 419 (6907): 587-593. 10.1038/nature01050.PubMedView ArticleGoogle Scholar
- Chan YY, Tan TM, Ong YM, Chua KL: BpeAB-OprB, a multidrug efflux pump in Burkholderia pseudomallei. Antimicrob Agents Chemother. 2004, 48 (4): 1128-1135. 10.1128/AAC.48.4.1128-1135.2004.PubMed CentralPubMedView ArticleGoogle Scholar
- Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE: Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob Agents Chemother. 1999, 43 (3): 465-470.PubMed CentralPubMedGoogle Scholar
- Lee A, Mao W, Warren MS, Mistry A, Hoshino K, Okumura R, Ishida H, Lomovskaya O: Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol. 2000, 182 (11): 3142-3150. 10.1128/JB.182.11.3142-3150.2000.PubMed CentralPubMedView ArticleGoogle Scholar
- Chan YY, Bian HS, Tan TM, Mattmann ME, Geske GD, Igarashi J, Hatano T, Suga H, Blackwell HE, Chua KL: Control of quorum sensing by a Burkholderia pseudomallei multidrug efflux pump. J Bacteriol. 2007, 189 (11): 4320-4324. 10.1128/JB.00003-07.PubMed CentralPubMedView ArticleGoogle Scholar
- Pagès JM, Masi M, Barbe J: Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol Med. 2005, 11 (8): 382-389. 10.1016/j.molmed.2005.06.006.PubMedView ArticleGoogle Scholar
- Nair BM, Cheung KJ, Griffith A, Burns JL: Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia). J Clin Invest. 2004, 113 (3): 464-473.PubMed CentralPubMedView ArticleGoogle Scholar
- Nair BM, Joachimiak LA, Chattopadhyay S, Montano I, Burns JL: Conservation of a novel protein associated with an antibiotic efflux operon in Burkholderia cenocepacia. FEMS Microbiol Lett. 2005, 245 (2): 337-344. 10.1016/j.femsle.2005.03.027.PubMedView ArticleGoogle Scholar
- Govan JR, Brown PH, Maddison J, Doherty CJ, Nelson JW, Dodd M, Greening AP, Webb AK: Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet. 1993, 342 (8862): 15-19. 10.1016/0140-6736(93)91881-L.PubMedView ArticleGoogle Scholar
- Guglierame P, Pasca MR, De Rossi E, Buroni S, Arrigo P, Manina G, Riccardi G: Efflux pump genes of the resistance-nodulation-division family in Burkholderia cenocepacia genome. BMC Microbiol. 2006, 6: 66-10.1186/1471-2180-6-66.PubMed CentralPubMedView ArticleGoogle Scholar
- Holden MT, Seth-Smith HM, Crossman LC, Sebaihia M, Bentley SD, Cerdeño-Tárraga AM, Thomson NR, Bason N, Quail MA, Sharp S, Cherevach I, Churcher C, Goodhead I, Hauser H, Holroyd N, Mungall K, Scott P, Walker D, White B, Rose H, Iversen P, Mil-Homens D, Rocha EP, Fialho AM, Baldwin A, Dowson C, Barrell BG, Govan JR, Vandamme P, Hart CA, Mahenthiralingam E, Parkhill J: The genome of Burkholderia cenocepacia J an epidemic pathogen of cystic fibrosis patients. J Bacteriol. 2315, 191 (1): 261-277. 10.1128/JB.01230-08.View ArticleGoogle Scholar
- Flannagan RS, Linn T, Valvano MA: A system for the construction of targeted unmarked gene deletions in the genus Burkholderia. Environ Microbiol. 2008, 10 (6): 1652-1660. 10.1111/j.1462-2920.2008.01576.x.PubMedView ArticleGoogle Scholar
- Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE: Efflux- mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob Agents Chemother. 1999, 43 (3): 465-470.PubMed CentralPubMedGoogle Scholar
- Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chamberland S, Renau T, Leger R, Hecker S, Watkins W, Hoshino K, Ishida H, Lee VJ: Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother. 2001, 45 (1): 105-116. 10.1128/AAC.45.1.105-116.2001.PubMed CentralPubMedView ArticleGoogle Scholar
- Coban AY, Ekinci B, Durupinar B: A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates. Chemotherapy. 2004, 50 (1): 22-26. 10.1159/000077280.PubMedView ArticleGoogle Scholar
- Piddock LJ: Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol. 2006, 4 (8): 629-636. 10.1038/nrmicro1464.PubMedView ArticleGoogle Scholar
- Bina XR, Provenzano D, Nguyen N, Bina JE: Vibrio cholerae RND family efflux systems are required for antimicrobial resistance, optimal virulence factor production, and colonization of the infant mouse small intestine. Infect Immun. 2008, 76 (8): 3595-3605. 10.1128/IAI.01620-07.PubMed CentralPubMedView ArticleGoogle Scholar
- Sokol PA, Sajjan U, Visser MB, Gingues S, Forstner J, Kooi C: The CepIR quorum-sensing system contributes to the virulence of Burkholderia cenocepacia respiratory infections. Microbiology. 2003, 149: 3649-3658. 10.1099/mic.0.26540-0.PubMedView ArticleGoogle Scholar
- Sambrook J, Russell DW: Molecular cloning: a laboratory manual. 2001, Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NYGoogle Scholar
- Craig FF, Coote JG, Parton R, Freer JH, Gilmour NJ: A plasmid which can be transferred between Escherichia coli and Pasteurella haemolytica by electroporation and conjugation. J Gen Microbiol. 1989, 135 (11): 2885-2890.PubMedGoogle Scholar
- McClean KH, Winson MK, Fish L, Taylor A, Chhabra SR, Camara M, Daykin M, Lamb JH, Swift S, Bycroft BW, Stewart GS, Williams P: Quorum sensing and Chromobacterium violaceum: exploitation of violacein production and inhibition for the detection of N-acylhomoserine lactones. Microbiology. 1997, 143 (Pt 12): 3703-3711. 10.1099/00221287-143-12-3703.PubMedView ArticleGoogle Scholar
- Aguilar C, Bertani I, Venturi V: Quorum-sensing system and stationary-phase sigma factor (rpoS) of the onion pathogen Burkholderia cepacia genomovar I type strain, ATCC 25416. Appl Environ Microbiol. 2003, 69 (3): 1739-1747. 10.1128/AEM.69.3.1739-1747.2003.PubMed CentralPubMedView ArticleGoogle Scholar
- Miller VL, Mekalanos JJ: A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J Bacteriol. 1988, 170 (6): 2575-2583.PubMed CentralPubMedGoogle Scholar
- Figurski DH, Helinski DR: Replication of an origin-containing derivative of plasmid RK2 dependent on a plasmid function provided in trans. Proc Natl Acad Sci U S A. 1979, 76 (4): 1648-1652. 10.1073/pnas.76.4.1648.PubMed CentralPubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.